Researchers at Cardiff University in the UK have developed a new method to test the likelihood of a drug turning into a potentially harmful version of itself when it enters the body.
ANI Pharmaceuticals has acquired the new drug applications (NDAs) and US marketing rights for AstraZeneca’s Atacand, Atacand HCT, Arimidex, and Casodex for $46.5m.
Mallinckrodt has signed a deal to acquire US-based Sucampo Pharmaceuticals for about $1.2bn to add the latter’s constipation medication Amitiza (lubiprostone) and other commercial and development assets to its portfolio.
Teva Pharmaceutical Industries said it will lay off 14,000 jobs globally as part of a two-year restructuring plan, aimed at boosting its business and financial performance.
Flexion Therapeutics has entered into a definitive agreement with GeneQuine Biotherapeutics GmbH to acquire the global rights to GQ-203.
Ardelyx has entered into a license agreement with Shanghai Fosun Pharmaceutical Industrial Development Company (Fosun Pharma) for tenapanor.
Arena Pharmaceuticals and Everest Medicines have entered into a development and commercialization partnership for ralinepag and etrasimod in mainland China, Taiwan, Hong Kong, Macau, and South Korea (the "Territories").
Melinta Therapeutics has agreed to acquire the infectious disease business from The Medicines Company.
The State of North Carolina and Fresenius Kabi have announced plans to expand the company's presence in Wilson, North Carolina.
Cerecor has entered into an agreement to TRx Pharmaceuticals and its subsidiary Zylera Pharmaceuticals.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.